Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of immune phenotype with IDH mutation in diffuse glioma.

Neuro-oncology - 19 Oct 2017

Berghoff Anna Sophie, Kiesel Barbara, Widhalm Georg, Wilhelm Dorothee, Rajky Orsolya, Kurscheid Sebastian, Kresl Philip, Wöhrer Adelheid, Marosi Christine, Hegi Monika E, Preusser Matthias

Abstract excerpt

BACKGROUND: Tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) are targets of immune checkpoint inhibitors. METHODS: Forty-three World Health Organization (WHO) grade II/III gliomas (39 IDH-mutant [mut], 4 IDH-wildtype [wt]) and 14 IDH-mut glioblastomas (GBM) were analyzed for TIL (CD3+; PD1+) infiltration and PD-L1 expression. Results were compared with the data of a previously published...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Cohort Studies

Share to Follow-Up Studies

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Lymphocytes, Tumor-Infiltrating

Source

Open in PubMed Open full text

Identifiers

PMID: 28531337
DOI: 10.1093/neuonc/nox054
PMCID: PMC5737620

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of immune phenotype with IDH mutation in diffuse glioma.PMID 28531337Read ↗

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.Semantic proximity Read ↗

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.Semantic proximity Read ↗

New insights into the Immune TME of adult-type diffuse gliomas.Semantic proximity Read ↗

Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.Semantic proximity Read ↗

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaSemantic proximity Read ↗

Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.Semantic proximity Read ↗

Programmed Death Ligand-1 Expression in Gliomas: A Study of Histopathological and Molecular Associations.Semantic proximity Read ↗

PD-1 related transcriptome profile and clinical outcome in diffuse gliomasSemantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse GliomasSemantic proximity Read ↗

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read ↗

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.